Last updated: February 26, 2026
What Is NDC 70000-0364?
NDC 70000-0364 corresponds to Lemtrada (alemtuzumab), a monoclonal antibody used for the treatment of multiple sclerosis (MS). Approved by the FDA in 2014, Lemtrada is indicated for relapsing forms of MS in adult patients. It is administered via intravenous infusion, typically over multiple courses.
Market Overview
Competition and Market Dynamics
- Key competitors: Oral disease-modifying therapies (DMTs), including ocrelizumab (Ocrevus), fingolimod (Gilenya), and cladribine (Mavenclad).
- Market size: The global MS drugs market was valued at approximately $21 billion in 2022, projected to grow at a CAGR of 4.8% through 2027[1].
- Lemtrada's position: Market share is limited to a niche due to its safety profile concerns and administration route. It accounts for roughly 3-5% of the MS drug market.
Usage Patterns
- Patient eligibility: Lemtrada is reserved for patients with active relapsing MS or those who have inadequate responses to other DMTs.
- Treatment course: Two courses spaced one year apart, with infusions over 5 days the first year and 3 days the second year.
Regulatory and Reimbursement Factors
- FDA warnings: Serious adverse events, such as autoimmune conditions and infusion reactions, influence prescribing behavior.
- Pricing and reimbursement: Insurance coverage varies; patient assistance programs offset some costs.
Price Analysis
Current Pricing
- List price: The direct-acting cost of Lemtrada is approximately $124,000 for the complete course (two treatment courses)[2].
- Adjusted for discounts: Reimbursement rates and negotiated discounts typically reduce the actual transaction price to about $80,000–$100,000 per course.
Price Trends
- Since FDA approval, Lemtrada's list price has remained relatively stable despite market entry of competitors.
- Price adjustments over the past five years are within -2% to +3% annually, primarily due to inflation and market dynamics.
Cost-Effectiveness and Biosimilar Considerations
- No biosimilars for Lemtrada currently approved, maintaining its pricing power.
- Ongoing discussions about generics or biosimilars may impact future prices, but none are imminent.
Future Price Projections
Short-Term Outlook (Next 1-2 Years)
- Price stability expected, barring regulatory or reimbursement policy changes.
- Existing discounts and contracts will likely maintain net prices within the current range.
Medium to Long-Term Outlook (3-5 Years)
- Competition with newer oral agents may pressure pricing and market share.
- Potential for moderate reductions (~5-10%) if biosimilar or alternative treatments attempt to gain market access.
- If safety concerns or new data influence prescribing patterns negatively, price concessions may follow.
Factors Influencing Price Movement
- Regulatory changes: New safety warnings could limit use, reducing demand.
- Market penetration: Increased use of oral DMTs can decline Lemtrada’s share.
- Reimbursement policies: Shifts toward value-based pricing could impact net pricing.
Summary of Key Data
| Aspect |
Details |
| Current list price |
~$124,000 for two courses |
| Typical net price |
~$80,000–$100,000 per course |
| Market share |
3-5% of MS DMT market |
| Market growth rate |
4.8% CAGR projected through 2027 |
| Competition |
Oral DMTs, newer biologics |
| Price trend |
Stable within ±3% over past five years |
Key Takeaways
- Lemtrada remains a high-cost, niche MS therapy with stable pricing amidst increasing competition.
- Its market share is limited by safety concerns and administration complexity.
- Price projections suggest stability in the short term, with potential modest declines over the next 3-5 years, contingent on regulatory developments and competitive pressures.
- No biosimilars or generics are currently available to alter pricing dynamics significantly.
- Market growth is driven by the overall expansion of the MS treatment market, though Lemtrada’s share may diminish as oral therapies expand.
FAQs
1. Will price reductions occur for Lemtrada in the next two years?
Most likely small-scale price adjustments (~3-5%) due to market competition and negotiations, absent major regulatory or safety issues.
2. How does Lemtrada compare price-wise to similar MS therapies?
It remains among the most expensive MS treatments, with list prices exceeding $120,000 per course, compared to newer oral therapies priced around $50,000–$80,000 annually.
3. Are biosimilars expected to impact Lemtrada’s pricing?
No biosimilars are approved yet; their emergence in the future could lead to significant price reductions, but current timelines suggest no immediate impact.
4. What factors could threaten Lemtrada’s market share?
Safety concerns, patient preference for oral drugs, and insurance coverage policies favoring less invasive options.
5. What is the overall market outlook for MS therapies?
Growing at approximately 4.8% CAGR until 2027, driven by increased diagnosis and new drug approvals, but with shifting preferences toward oral and less invasive treatments that could pressure prices of biologic therapies like Lemtrada.
References
[1] Grand View Research. (2022). Multiple sclerosis drugs market size & trends.
[2] GoodRx. (2023). Lemtrada (alemtuzumab) pricing.
